Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > Approval timing..
View:
Post by SMlachake on Jul 19, 2022 10:36am

Approval timing..

Anyone aware of any historical data as to how long it takes for a device approval once it acquires Breakthough designation? For this designation, plenty of data must have already been reviewed. And the device is approved in jurisdictions with similar standard of Healthcare Japan, Europe and Canada. It's just a matter of time.
Comment by mercedesman on Jul 19, 2022 10:52am
The short answer is, it gets approved when the Trial is over (after sufficient enrollment). However there is more to it than that... 100 patients come from Euphrates (Phase 3)  150 come from Tigris (Phase 3b) Kellum says we are approachigin 1/3 enrollment for Tigris (that's 50 on my calculator) So 150 enrolled /250 needed = 60% complete. There will be an Interim Review at 90 patients ...more  
Comment by SMlachake on Jul 19, 2022 11:54am
Thank you. That was a detailed answer. If my assumptions are correct, it only takes a few hours to collect data per patient which the FDA is eagerly waiting to process. So the only delay is participants and unfortunately there is never a shortage of patients. I now see why this could be complete any day. Great.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities